Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June closed on a high note for the stock market, with the S&P 500, tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY), gaining 3.2%, despite significant disparities in sector and industry performances.T
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $56
TD Cowen analyst Ritu Baral maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and sets the target price at $56.According to TipRanks data, the analyst has a success rate of 45.0% and a total
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
Have Insiders Sold Avidity Biosciences Shares Recently?
We'd be surprised if Avidity Biosciences, Inc. (NASDAQ:RNA) shareholders haven't noticed that the Chief Human Resources Officer, Teresa McCarthy, recently sold US$386k worth of stock at US$39.13 per s
Avidity Biosciences(RNA.US) Director Sells US$187.95K in Common Stock
$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 5,000 shares of common stock on Jun 20, 2024 at an average price of $37.5901 for a total value of $187.95K.Source: Announcement What is state
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Insider Sold Shares Worth $1,255,040, According to a Recent SEC Filing
Sarah Boyce, Director, President and Chief Executive Officer, on June 17, 2024, sold 32,074 shares in Avidity Biosciences (RNA) for $1,255,040. Following the Form 4 filing with the SEC, Boyce has cont
(RNA) - Analyzing Avidity Biosciences's Short Interest
Avidity Biosciences's (NYSE:RNA) short percent of float has fallen 4.33% since its last report. The company recently reported that it has 10.82 million shares sold short, which is 14.81% of all regula
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 17, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Avidity Biosciences, Inc. (NASDAQ:RNA) shares jumped 50.15% following the announcement that the Phase 1/2 tri
Avidity Biosciences(RNA.US) Officer Sells US$3.72 Million in Common Stock
$Avidity Biosciences(RNA.US)$ Officer MacLean Michael F sold 104.25K shares of common stock on Jun 12, 2024 at an average price of $35.7153 for a total value of $3.72 million.Source: Announcement What
Avidity Biosciences(RNA.US) Director Sells US$3.81 Million in Common Stock
$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 100K shares of common stock on Jun 12, 13, 2024 at an average price of $38.0741 for a total value of $3.81 million.Source: Announcement What
Avidity Biosciences(RNA.US) Officer Sells US$11.59 Million in Common Stock
$Avidity Biosciences(RNA.US)$ Officer Boyce Sarah sold 300K shares of common stock on Jun 12, 13, 14, 2024 at an average price of $38.6277 for a total value of $11.59 million.Source: Announcement What
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO, June 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $75
Wells Fargo analyst Yanan Zhu maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and adjusts the target price from $50 to $75.According to TipRanks data, the analyst has a success rate of 46.1
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:Adobe Inc. (NASDAQ:ADBE) posted upbeat results for its second quarter
Avidity Biosciences Raises $400M via Stock Offering
Express News | Avidity Biosciences Inc - Pricing of an Underwritten Public Offering of 10.55 Mln Shares of Its Common Stock at a Price to Public of $38.00 per Share